Scott Turner

Scott Turner

Company: Pliant Therapeutics

Job title: Senior Vice President of Research


Reprograming the immunosuppressive tumour microenvironment with selective integrin inhibition 2:00 pm

Inhibition of avb8 and avb1 promotes ifng and suppresses tgfb signalling in tumors Reprograming tumor cytokine levels promotes proinflammatory cell infiltration and suppress stromal protein synthesis Treatment was synergistic with checkpoint inhibitors in multiple murine tumor modelsRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.